The clinical benefit of therapeutic cancer vaccines has been established. Whereas regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in cancer patients was mostly noted as prolonged survival. Suboptimal vaccine design and an immunosuppressive cancer microenvironment are the root causes of the lack of cancer eradication. Effective cancer vaccines deliver concentrated antigen to both HLA class I and II molecules of DCs, promoting both CD4 and CD8 T cell responses. Optimal vaccine platforms include DNA and RNA vaccines and synthetic long peptides. Antigens of choice include mutant sequences, selected cancer testis antigens, and viral antigens. Drugs or physical treatments can mitigate the immunosuppressive cancer microenvironment and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors of T cell checkpoints, agonists of selected TNF receptor family members, and inhibitors of undesirable cytokines. The specificity of therapeutic vaccination combined with such immunomodulation offers an attractive avenue for the development of future cancer therapies.
Therapeutic cancer vaccines

Cornelis J.M. Melief,1,2 Thorbald van Hall,1 Ramon Arens,1 Ferry Ossendorp,1 and Sjoerd H. van der Burg1

1Leiden University Medical Center, Leiden, Netherlands. 2ISA Pharmaceuticals, Leiden, Netherlands.

The clinical benefit of therapeutic cancer vaccines has been established. Whereas regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in cancer patients was mostly noted as prolonged survival. Suboptimal vaccine design and an immunosuppressive cancer microenvironment are the root causes of the lack of cancer eradication. Effective cancer vaccines deliver concentrated antigen to both HLA class I and II molecules of DCs, promoting both CD4 and CD8 T cell responses. Optimal vaccine platforms include DNA and RNA vaccines and synthetic long peptides. Antigens of choice include mutant sequences, selected cancer testis antigens, and viral antigens. Drugs or physical treatments can mitigate the immunosuppressive cancer microenvironment and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors of T cell checkpoints, agonists of selected TNF receptor family members, and inhibitors of undesirable cytokines. The specificity of therapeutic vaccination combined with such immunomodulation offers an attractive avenue for the development of future cancer therapies.

Introduction
Preventive vaccination against infectious diseases is considered one of the most successful health measures of all time. Therapeutic vaccination against established diseases such as persistent infections and cancer has proven much more challenging, because the vaccine intervention must combat an immune system that has been restrained by tolerizing or polarizing mechanisms that sustain the disease in a misguided attempt at self-tolerance. Nevertheless, recent clinical results indicate that the era of successful therapeutic vaccination has arrived. In this Review, we discuss the most attractive preclinical and clinical therapeutic vaccination strategies, as well as opportunities to improve such therapies. With the exception of some forms of premalignant disease, the proportion of patients benefiting from treatment with cancer vaccines, in addition to the mean survival advantages, leaves much to be desired. Better results can most likely be obtained by a better choice of antigens, improvements in vaccine design, and appropriate cotreatments. The latter can alleviate immunosuppressive mechanisms in the cancer microenvironment and boost vaccine performance by appropriate stimulation or modulation of the immune system.

Clinical cancer vaccines against nonviral antigens
Antigens on nonviral cancers are targeted for immunotherapy, including vaccines, for two main reasons: (a) the antigens can elicit an immune response that selectively attacks cancer cells, and (b) these antigens are (over-)expressed on cancer cells. If such antigens are expressed at all on normal cells, as in the case of differentiation antigens, the immune response to the normal tissues should only cause nonlethal side effects, such as vitiligo in the case of immune responses elicited against melanocyte antigens. A recent review has detailed clinical therapeutic vaccination studies in patients with nonviral cancers (1). In many phase I/II studies, these vaccines have shown clinical benefit, in particular extended overall or disease-free survival, while objective durable regressions of the type associated with targeted or immunomodulatory mAb therapy (2–6) or chimeric antigen receptor (CAR) (7–10) or adoptive T cell (11, 12) therapy were rarely seen.

Vaccines for nonviral cancers have targeted shared antigens. Vaccines against nonviral cancers have largely utilized target molecules, such as differentiation antigens, cancer testis (CT) antigens, or overexpressed antigens (1), that are common to a particular cancer type. A list of antigens commonly used in therapeutic vaccination against nonviral cancers is provided in Table 1 and refs. 1 and 13–24.

Central immunological tolerance mechanisms shape the T cell repertoire that recognizes these antigens (20, 25–27); thus, the T cells induced by these vaccines must rely on the T cell repertoire left after the induction of central tolerance, which depletes many, but not all, of the high-avidity T cells directed against such antigens. Indeed, overexpressed CT or differentiation antigens were found in medullary thymic epithelial cells that express virtually all self-molecules (25, 27), including cancer–associated antigens (28), although epitope expression failure can occur in the thymus (29). Nevertheless, deletional immunological tolerance of the T cell repertoire toward self-antigens is the rule rather than the exception.

Despite the likelihood of elimination through central tolerance mechanisms, adequate T cell repertoires are available to allow clinical benefit. Provenge (sipucleucel-T), which targets the prostate differentiation antigen prostate acid phosphatase (PAP), was the first cancer vaccine to be approved in the US and Europe on the basis of its capacity to prolong overall survival in patients with hormone-resistant prostate cancer by an average of 3 months (22). This vaccine is a cellular product generated from autologous...
peripheral blood monocytes (PBMCs) by culturing with a fusion protein of PAP linked to granulocyte-macrophage CSF (GM-CSF). The exact mode of action is not known, because the cultured PBMCs contain both partially activated DCs and T cells as well as other peripheral blood cellular components. At any rate, vaccination increased the number of PAP-specific T cells in the prostate (30). PROSTVAC-VF (TRICOM, Bavarian Nordic, exclusive option of BMS) (31, 32) is a cancer vaccine that consists of two recombinant viral vectors. Each vector encodes prostate-specific antigen (PSA) and three costimulatory molecules (CD80, ICAM-1, and LFA-3). Priming is achieved by a vaccinia virus vector, followed by a boost with fowlpox vector. Such a heterologous prime-boost protocol ensures that the response against the tumor-associated antigen (TAA), the only antigen shared between the two viral vectors, is enhanced by the boost. An increase in PSA-doubling time was observed that was associated with a survival benefit of 8.5 months in the vaccinated group versus a control group of patients with hormone-resistant prostate cancer (21).

Therapeutic vaccines have also been evaluated in patients with breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, and renal cancer (1). A survival advantage was seen with some vaccines in phase II trials that was sometimes associated with an immune response to the vaccine in renal cell carcinoma (33), but no objective cancer regressions were noted. Survival advantage was also noted in a study of an HLA-A2-binding gp100-derived short peptide vaccine together with IL-2, versus treatment with IL-2 alone in patients with advanced melanoma (34). Target antigens for different cancers are listed in Table 1.

Mesothelin is a cell-surface molecule that is overexpressed on a variety of malignancies, including mesothelioma, pancreatic cancer, colorectal cancer, and ovarian cancer. Cancer regressions without appreciable toxicity were seen with an Ab-based immuno toxin that targeted mesothelin (36, 37), which, in theory, have the advantage of incorporating the full range of neoantigens resulting from somatic mutations, without having to identify these neoantigens directly. The disadvantage is that one does not know how effective the processing of neoantigen epitopes from the lysate is for effective DC presentation. Also, the lysate, if presented in a highly immunogenic vaccine formulation, may conceivably induce autoimmunity to autoantigens also represented in the lysate.

In hematological malignancies, vaccination against the idiotype of monoclonal surface Ig on malignant B cells has been associated with prolonged disease-free survival in a phase III vaccine trial (38). However, regular anti-B cell mAbs, bispecific T cell–enhancing (BITE) Abs (39), and CARs targeting CD19 will likely supplant anti-idiotype approaches because of off-the-shelf availability or greater effectiveness.

In considering other vaccine approaches, in particular DC vaccines, it is noteworthy that Wilms tumor-1 (WT-1) peptide vaccination or vaccination with DCs electroporated with WT1 mRNA in patients with acute myelogenous leukemia (AML) has led to occasional leukemia regression (40, 41) or conversion from partial to complete remission following vaccination (42). Therapeutic vaccination with ex vivo–prepared tumor antigen–loaded DCs, particularly in patients with metastatic melanoma, has been practiced by numerous groups, mainly with monocyte-derived, in vitro–cultured DCs. Recently, a shift from such DCs to natural DC subsets occurring in blood and similarly loaded with TAAAs has shown a trend toward better clinical results (43). Also, whereas ex vivo–generated DCs were mostly loaded with class I MHC epitopes, CD4+ Th cell targeting has improved the clinical results (44). These results were confirmed by a study of in vitro interactions between DCs and CD4+ T cells (45). A skin test measuring infiltration by antigen-driven T lymphocytes reportedly predicts patient survival (46). DC vaccination with mRNA-encoding melanocyte-associated antigens electroporated into DCs following complete resection of metastases has shown encouraging survival results (47). However, apart from the results with sipuleucel-T, which hardly qualifies as a DC vaccine sensu stricto, no successful phase III trial results have been reported for DC-based cancer vaccines.

Emerging neoantigens for therapeutic vaccination against nonviral cancers. In the hierarchy of therapeutic vaccine targets in nonviral cancers, powerful arguments for selecting neoantigens (based on mutation) in addition, or even exclusively, whenever possible, were recently provided by both preclinical and clinical observations. Vaccines against mutation-based neoantigens are
viruses and other infectious agents such as antigens that are likely responsible for, or heavily contribute to, human oncogenic virus types: hepatitis B virus (HBV) and HPV. Notably, preventative vaccines are available for only two of the vaccines, but no efficacy data are available as of this writing (64). HBV and HCV do not contain oncogenic proteins unique to each patient, because the mutations induced by carcinogens or UV light are random. Of course, the preparation of personalized vaccines poses new challenges.

The first evidence of the potential of neo-epitope vaccination was made in the B16 mouse melanoma model, in which synthetic long peptide (SLP) vaccination against two mutant antigens was associated with a marked antitumor effect (48, 49). More recently, in preclinical mouse experiments with a chemically induced escape variant tumor that had lost a major mutant rejection epitope, tumor rejection could still be achieved by Ab-mediated immune checkpoint blockade (anti–CTLA-4 or anti–PD-1). This effective treatment was demonstrated to act by reactivation of existing T cells against two other mutant CTL epitopes (50). Interestingly, the same therapeutic effect was also accomplished by vaccination with two SLPS incorporating these two mutant epitopes together with TLR3 ligand polynosinic polycytidylic acid (poly I:C) (50). Similar observations were made in an independent mutation-based cancer model (51). Likewise, in a clinical study of patients with metastatic melanoma, clinical benefit from treatment with anti–CTLA-4 was strongly associated with a high mutational load in the patients' cancer, indicating that the responses to neoantigens that were unleashed by the anti–CTLA-4 treatment were clinically useful (52, 53). Anti–CTLA-4 treatment of patients with metastatic melanoma reportedly broadens the T cell responses to shared antigens such as overexpressed antigens, differentiation antigens, and CT antigens (54). The contribution to clinical success of this broadening, next to the arousal of T cell responses against neoantigens, is currently unknown, although evidence is emerging that adoptive T cell therapy with T cells directed against mutations is more effective than that directed against differentiation antigens. In any case, it has now been shown beyond doubt that tumor-infiltrating lymphocytes (TILs) from melanoma patients that successfully eradicate tumors frequently contain CD8+ or CD4+ T cells against neoantigens that are likely responsible for, or heavily contribute to, anticancer effects (53, 55–57).

**Antigens of choice in virus-induced cancers.** Cancers caused by viruses and other infectious agents such as *Helicobacter pylori* constitute approximately 20% of all cancers worldwide (58, 59). A list of the currently identified cancer viruses is shown in Table 2. Notably, preventative vaccines are available for only two of the human oncogenic virus types: hepatitis B virus (HBV) and HPV. Therapeutic vaccines against the viruses listed in Table 2 are attractive for the treatment of persistent viral infection or (pre-)malignant disease.

**Clinical experience with therapeutic vaccines against human cancer viruses**

**HBV and hepatitis C virus vaccines.** Despite the fact that preventive vaccines for HBV have been available for approximately 32 years, hundreds of millions of individuals worldwide are still persistently infected with HBV (60). Thus, therapeutic vaccines will be needed for years to come.

Several types of therapeutic vaccines against persistent HBV infection and its sequelae have been developed. These vaccine platforms include recombinant HBV proteins, DNA vaccines, recombinant virus vaccines, and subviral particles, as well as immune complexes of HBV surface antigen (HBsAg) and IgG anti-HBsAg (reviewed in ref. 61). Immune complex targeting through Fc receptors facilitates both DC ingestion of antigen and DC activation. Vaccination with these immune complexes consisting of HBsAg and IgG Abs yielded promising results in a phase II trial (62), but a phase III randomized trial showed no clinical or virological benefit in patients persistently infected with HBV (63). Therapeutic vaccines against hepatitis C virus (HCV) have utilized by and large the same vaccination platforms as those for vaccines against HBV (64). So far, good immunogenicity data have been collected for some vaccines, but no efficacy data are available as of this writing (64). HBV and HCV do not contain oncogenic proteins that need to remain expressed in the transformed cells, but rather cause hepatocellular cancer (HCC) by indirect mechanisms such as inflammatory events. This necessitates targeting persistent viral infection before malignant transformation, because HCC may not necessarily express viral proteins.

**EBV vaccines.** Immunotherapy for malignant disease caused by EBV is a classical success story for adoptive transfer of EBV-specific T cells in diseases such as post-transplantation EBV-induced lymphomas (11), but therapeutic vaccination against EBV-related diseases is still relatively underdeveloped. A report was published more than 10 years ago regarding a vaccine candidate consisting of a recombinant pox virus vector incorporating the EBV antigens EBNA-1 and LMP2 that elicited both CD4+ and CD8+ T cell responses against EBV. Recent results from two different phase I toxicity/immunogenicity trials testing this vaccine in patients with

---

**Table 2. Human oncogenic viruses, associated diseases, and vaccine targets**

<table>
<thead>
<tr>
<th>Virus</th>
<th>Human T lymphotropic virus</th>
<th>HBV</th>
<th>HCV</th>
<th>HPV</th>
<th>KSV</th>
<th>Merkel cell carcinoma virus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of virus</strong></td>
<td>Herpes virus</td>
<td>Retrovirus</td>
<td>Hepadna virus</td>
<td>RNA flavivirus</td>
<td>Papilloma virus</td>
<td>Herpes virus</td>
</tr>
<tr>
<td><strong>Associated diseases</strong></td>
<td>Nasopharyngeal carcinoma, B cell lymphomas, Hodgkin's disease</td>
<td>Adult T cell leukemia, lymphoma</td>
<td>Cytosis, hepatocellular cancer</td>
<td>Cytosis, hepatocellular cancer</td>
<td>Anogenital cancer, head and neck cancer</td>
<td>Sarcomas in immunodeficient individuals</td>
</tr>
<tr>
<td><strong>Therapeutic vaccine targets</strong></td>
<td>LMP1A, LMP2A</td>
<td>Tax protein</td>
<td>All HBV proteins</td>
<td>All HCV proteins</td>
<td>E6 oncoproteinA, E7 oncoproteinA</td>
<td>All KSV proteins</td>
</tr>
</tbody>
</table>

*Oncogenic proteins. LMP1/2, late membrane protein 1/2. KSV, Kaposi sarcoma virus.
EBV-induced nasopharyngeal carcinoma (NPC) or other EBV-induced malignancies (65–67) showed that the vaccine was well tolerated and elicited antigen-specific T cell responses. An EBV vaccine could potentially prevent the development of EBV-induced malignancies, even if it does not prevent transmission of the virus (68). Considering the high proportion of individuals persistently infected with EBV (68), it is surprising how few groups actively work on the development of effective EBV vaccines.

Human T lymphotropic virus-I vaccines. Human T lymphotropic virus-I (HTLV-I) is a retrovirus that causes adult T cell leukemia/lymphoma (ATLL) or spastic paresis in a small proportion of persistently infected individuals. In a recent study, three patients with ATLL who were previously treated with conventional chemotherapy were subsequently vaccinated with DCs loaded with HLA-A2 epitopes of the viral tax protein, which is involved in both neoplastic transformation and spastic paresis induction. Two of these patients showed a partial response and the third later achieved a durable, complete response (69).

Merkel cell carcinoma virus vaccine. The Merkel cell carcinoma virus was only recently identified as the cause of a rare, rapidly metastasizing skin cancer (70, 71). It generates two virus-encoded oncoproteins: large T and small T. A patient with metastatic Merkel cell carcinoma could be successfully treated by adoptive transfer of T cells directed against the virus in combination with intratumoral injection of IFNβ-1b or low-dose lesion irradiation (72). In a preclinical therapeutic vaccination model, mice bearing small T–expressing B16 melanoma tumors lived significantly longer after DNA vaccination with a construct encoding small T than did animals that were vaccinated with empty vector. Small T vaccination was associated with substantial T cell response induction. This model is likely to predict clinical efficacy for this aggressive cancer type, because small T is as much a foreign antigen to patients as it is to mice (73).

HPV vaccines. Preventive HPV vaccines have been offered to 10- to 12-year-old girls for the past decade; however, compliance with vaccination is far from 100%, and the vaccines covering the high-risk types of HPV (HPV16 and -18, which are implicated in more than 50% of all cervical cancers) have not yet been introduced in those parts of the world where they are needed the most. Even in the Western world, many individuals are persistently infected with high-risk HPV and are at risk of developing cervical cancer and HPV-positive head and neck cancer due to incomplete vaccination coverage and to the large cohort of infected individuals from the pre-HPV vaccine era (74–76).

The largest number of clinical studies using therapeutic vaccines in virally induced premalignant disease or cancer has been conducted to examine high-risk HPV, in particular HPV16, a virus responsible for approximately 50% of cervical carcinomas and 80% of HPV-positive head and neck cancers (reviewed in refs. 77–82). Thus far, the best immunogenicity in terms of CD4+ and CD8+ T cell responses and clinical responses was seen in patients with premalignant diseases such as cervical intraepithelial neoplasia (CIN) or vulvar intraepithelial neoplasia (VIN). Vaccination with SLPs that overlap the entire sequence of the E6 and E7 oncoproteins delivered s.c. in Montanide ISA-51 adjuvant induced robust CD4+ Th responses against many epitopes of these proteins and a somewhat less broad CD8+ T cell response (83, 84). More than 50% of patients had achieved partial or complete regression of lesions at three months after vaccination, and this percentage was even greater at twelve months after the last vaccine dose (83, 84). Moreover, there was a highly significant correlation between the strength of the vaccine-induced T cell immune response and the clinical response (83, 84). Interestingly, in patients with recurrent cervical cancer, this vaccine was much less immunogenic, and the induced T cell responses remained below the levels seen in VIN patients with clinical responses; indeed, vaccination did not confer a survival benefit of vaccination compared with historical controls (85). This illustrates one of the main problems in therapeutic cancer vaccination: cancer-associated alternation of systemic and local immunity appears to have a deleterious effect on T cell immunocompetence. In the treatment of VIN, results similar to those with SLP vaccination were achieved by application of Imiquimod ointment on the lesions, followed by vaccination with TA-CIN, a fusion protein of HPV16 E6 and E7 and the viral capsid protein L2 (86). DNA vaccines delivered by electroporation also induced a robust T cell response (87, 88) and lesion regression, together with virus clearance (88). Another promising vaccine is based on recombinant Listeria-E7 bacteria (89).

CMV vaccines. In recent years, CMV expression was reported in a high proportion of patients with glioblastomas. Although no causal role of CMV in the genesis of these tumors has been established, an oncomodulatory role is possible, and CMV antigens in these tumors can serve as targets for cancer vaccines (90, 91).

Common themes in therapeutic vaccines against human cancer viruses. Like the vaccines directed against neoantigens, the therapeutic vaccines against cancer viruses are directed against viral proteins that are not subject to central thymic tolerance. Moreover, many of these vaccines are directed against viral structures involved in malignant transformation (Table 2). This advantage can be exploited, because the vaccine can deliver antigen and stimulate robust effector T cell responses, whereas the natural infection is subject to the myriad intricate immune evasion and immunosuppression mechanisms these viruses have developed in the course of evolution (92–98). Nevertheless, these vaccines have to work against the same peripheral cell tolerance–, anergy–, and suppression–driving mechanisms operating in nononcogenic, persistent viral infections and nonviral cancers. These mechanisms include checkpoint suppression of T cells (4–6, 50, 99–101), Tregs (102), myeloid-derived suppressor cells (MDSCs) (103, 104), immunosuppressive cytokines such as TGF-β (105, 106) and IL-10 (107–109), and indoleamine 2,3-dioxygenase (IDO) (110–112), as well as lack of T cell infiltration at cancer sites (113–116) and improper inflammation (e.g., IL-6 mediated) (117–119).

Guidelines for the development of successful therapeutic cancer vaccines

Therapeutic cancer vaccines must achieve sufficient antigen concentration in DCs. Therapeutic vaccines need a rational vaccine design that achieves concentrated antigen delivery to DCs and DC activation, which in turn drives both CD4+ and CD8+ T cell responses (Figures 1 and 2). CD4+ T cells are needed for optimal and sustained effector CD8+ T cell responses (120–124) as well as induction and maintenance of CD8+ memory (125, 126).
Quite apart from these CD8+ T cell–supporting roles, CD4+ T cells have intrinsic effector functions (121, 127). Despite these insights, many therapeutic cancer vaccines have consisted of short, exact HLA class I–binding peptides (usually HLA-A2 binding), which do not induce CD4+ T cells, resulting in short-lived CD8+ T cell responses.

Short peptides (<15 amino acids) do not require processing by professional antigen-presenting cells (APCs) and therefore bind exogenously to the HLA class I molecules of all nucleated cells that have surface HLA class I. Thus, most of these injected short peptides will end up in nonphysiologically large numbers, clogging the appropriate HLA class I molecules of nonprofessional APCs in the absence of costimulatory molecules. This is basically a tolerizing signal, as we have previously shown (128–130). In the case of short peptide vaccination in incomplete Freund’s adjuvant (IFA), the T cells elicited by vaccination traveled to the vaccination site instead of to the tumor and appeared to die there (131). In the same study (131), vaccination with SLPs did not lead to such tolerance and was associated with proper antitumor activity, completely in line with our findings with short and long peptides in IFA (128).

Indeed, effector CD8+ T cell induction by short peptides and the associated antitumor effect is much less efficient than what is observed following vaccination with long peptides encompassing the same CD8+ T cell epitope. Also, vaccination with long peptides in IFA or its close relative Montanide ISA-51 supports robust T cell responses to SLPs, but not to most short peptides (128, 131–135). Only ex vivo loading of preactivated DCs with short peptides (136) or replacement of the CD4+ helper signal with agonist anti-CD40 Ab, with or without TLR ligand poly I:C (137, 138) or with CpG (139), can circumvent such tolerance induction against short, MHC class I–binding peptides in mice or patients.

SLPs (>20 amino acids) are pro-drugs in the sense that they are not biologically active by themselves, but need additional processing to allow loading in DC HLA molecules. The antigen presentation resulting from SLP vaccination reflects physiological pathways associated with much lower, and therefore more appropriate, MHC-ligand presentation than the uncontrollable and usually too-high peptide loading resulting from short peptide vaccination (Figure 2). We and others have shown that only DCs are capable of efficiently processing such SLPs for presentation in both MHC class I and class II molecules (140, 141) and that such processing is much more efficient than that of intact proteins (141, 142). Moreover, SLPs typically harbor both CD4+ and CD8+ T cell epitopes, ensuring that vaccination with SLPs induces a balanced CD4/CD8 response.

Cancer vaccines must utilize an effective route of administration. The preferred routes of cancer vaccine administration must effectively target the antigen to DCs (Figures 1 and 2). This is best achieved by s.c. administration or by delivery into DC-rich lymph nodes (reviewed in ref. 143). Other effective routes include s.c. long peptide delivery in Montanide (83). DNA vaccines have also been delivered effectively by i.m. injection in combination with electroporation (87, 88). An important consideration is the extent to which adjuvants and vaccination routes contribute to the proper circulating and tissue-resident CD4+ and CD8+ T cells with a homing preference for the proper cancer-infiltrated tissues. Considerable insights into the different T cell subsets and specific tissue-homing patterns have been obtained from mouse infection models (reviewed in ref. 144). Recent data show that mucosal cancers are best treated by vaccines that endow T cells with mucosal homing properties (145), but much more work is needed before solid rules for more efficient homing to cancerous tissues are incorporated into human cancer vaccine designs.
Therapeutic cancer vaccines must activate DCs with adjuvants. A crucial requirement of the proper action of SLP vaccines is the inclusion of appropriate adjuvants, including TLR ligands such as poly I:C (TLR3 ligand), CpG (TLR9 ligand) (50, 132–135, 146), Montanide (77–81, 83, 84, 132–135), or stimulator of IFN genes (STING) agonists (147). SLP vaccines can be further improved by the covalent coupling of a powerful TLR ligand to the peptide, leading to superior DC targeting and simultaneous DC activation (148–150). DNA or RNA vaccines contain more or less powerful built-in DC activators such as TLR ligands and pattern recognition receptors (PRRs) (reviewed in refs. 151, 152). Other popular cancer vaccines, including PROSTVAC, have utilized viral vectors; however, while such vectors contain numerous PRR ligands capable of DC activation (152), they also contain sequences that compete with the inserted TAAs (78, 153). Although PROSTVAC extended patient survival (21), the performance of vaccines incorporating this prostate antigen may conceivably be improved by excluding potentially competing vector sequences and incorporating strong immunostimulants. Heterologous prime boosting overcomes this problem to some extent (21).

Cancer vaccines based on recombinant protein delivery have also been used extensively, such as in the MAGE-A3 recombinant protein vaccination trials, in patients with metastatic melanoma or metastatic lung cancer. Recombinant protein vaccines suffer from the serious disadvantage that processing of such proteins by DCs for presentation by HLA class I molecules to CD8 T cells is very inefficient, as illustrated in the case of the MAGE-A3 vaccine by

Figure 2. Processing of vaccine-derived antigens. For antigen loading in HLA class I molecules, antigen must enter the DC cytoplasm to be processed by the proteasome complex. Longer antigen fragments are cut down by the proteasome to smaller, 9- to 15-amino acid stretches that can be pumped through the transporter of antigen processing (TAP), thereby gaining access to the endoplasmic reticulum, where HLA class I loading with fragments of 9 to 12 amino acids takes place, followed by transport to the cell surface. For antigen loading in HLA class II molecules, the antigen must enter the endosomal system, where cathepsins digest the antigen, followed by loading of HLA class II with fragments of approximately 12 to 15 amino acids at low pH and, following DC maturation, transport to the cell surface. Once DCs have fully matured, they interact with CD8+ and CD4+ T cells by stimulating the TCR with antigen presented by HLA class I or II molecules, respectively, and costimulatory molecules such as CD28. Activated, primed CD8+ T cells are then capable of killing tumor cells via ligation of the TCR with antigen presented by HLA class I molecules.
the lack of a demonstrable CD8 T cell response (154, 155). Moreover, the primary endpoint (extension of disease-free survival) was not met in phase III MAGE-A3 protein vaccination trials (156–158).

In view of the overwhelming importance of activated DCs in the initiation of therapeutic CD4+ and CD8+ T cell responses (Figures 1 and 2), an attractive strategy consists of isolating these cells, loading them with antigen, activating and maturing them appropriately, and then administering them as a therapeutic vaccine to cancer patients. Although Provenge has been advertised as a DC vaccine, it is a rather complex cellular product whose mode of action has not been well defined. Other DC vaccines have been very well defined and in several instances have shown promising therapeutic results, mainly in patients with metastatic melanoma (43–47, 159). Although DC vaccines may become a successful treatment modality, the manufacture of such personalized vaccines is expensive and laborious and requires a sophisticated good manufacturing practices (GMP) setting. Thus, we argue that such vaccines can serve as proof-of-concept and mode-of-action studies, but they eventually need to be replaced by antigen delivery and DC activation systems, such as SLP-TLR ligand conjugates, that directly target the DCs in vivo (148, 149).

In summary, with noted exceptions, the design of many cancer vaccines has insufficiently heeded the rules for efficient antigen processing and presentation in DCs for proper CD4+ and CD8+ effector and memory T cell induction and, by that criterion alone, have fallen short of one of the most important conditions for success.
Therapeutic cancer vaccines cannot be expected to act as a monotherapy. Cancer vaccines have been vilified because they do not approach the effectiveness of adoptive T cell transfer (160). However, the antigen specificity of adoptively transferred T cells (frequently expanded TILs) appears to determine the therapeutic efficacy of TILs. Recent evidence indicates that in a substantial number of cases, TILs are likely to have been directed against neoantigens (refs. 53, 57 and E.M. Verdegaal and S.H. van der Burg, personal communication), rather than against the shared antigens utilized as targets for most therapeutic vaccines against nonviral cancers. Indeed, persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in patients (161). On the other hand, in metastatic melanoma patients, immunotherapy with adoptive transfer of T cells transduced with an avidity-enhanced, NY-ESO-1–specific T cell receptor (TCR) produced marked, durable tumor regression (12), indicating that CT antigens such as NY-ESO-1 may be better targets for immunotherapy than differentiation antigens. Personalized vaccines against immunodominant CD4+ Th and CD8+ CTL epitopes representing neoantigens may indeed have a greater chance of therapeutic success, as was recently shown with SLP vaccines in mouse models (50, 51, 162). Development of personalized vaccines will create novel logistical and regulatory challenges that will likely be overcome by new technologies for rapid epitope prediction and validation from cancer exome sequences (50, 51).

Effective adoptive T cell transfer therapy requires drastic lymphopenia, implemented by heavy pretreatment with chemotherapeutics and/or total body x-ray irradiation or IFN-α conditioning (163, 164). It is unreasonable to demand that cancer vaccines be effective without a similarly profound restructuring of the cancer microenvironment (Figure 3). Thus, additional treatment is a necessity, not only to allow the vaccines to induce proper effector and memory T cell populations in the systemic circulation, but also to allow these cells to migrate to the cancer sites and exert tumoricidal activity. Lymphopenia is obviously not the answer; however, many standard chemotherapeutic agents such as thalidomide derivatives and other targeted compounds are known to deplete immunosuppressive Tregs and/or MDSCs without affecting effector T cell and memory T cell populations (Figure 3B). Not surprisingly, such depletion sets the stage for improved performance of immunotherapies, including simultaneous therapeutic vaccination (reviewed in ref. 165). An additional mechanism of improved tumor eradication by chemoinmunotherapy is cisplatin-mediated lowering of the tumor apoptosis threshold by TNF-α released from vaccine-induced intratumoral T cells (166). Another obvious choice for combination treatment is the addition of checkpoint-blocking agents to therapeutic vaccination, which has yielded promising results in preclinical models (Figure 3B and refs. 167–169). The combination of therapeutic vaccines with mAbs targeting selected TNF receptor family members (CD40, refs. 138, 170, 171; 4-1 BB/CD137, refs. 172–174;OX-40/CD134, refs. 172, 174–176; and CD27, refs. 177, 178) or immunosuppressive cytokines (IL-10, refs. 179, 180; TGF-β, refs. 181–183; IL-6, refs. 184, 185) is also an attractive approach (Figure 3B). Finally, the combination of a cancer vaccine with γC cytokines such as IL-7, IL-15, and IL-21 or IL-2 (186) may also be effective, because each of these cytokines has the capacity to expand antigen-experienced T cells.

Epilogue. Despite designs that are frequently suboptimal, cancer vaccines have shown clinical activity, particularly in the increase of recurrence-free or overall survival. Obvious choices for the design of powerful cancer vaccines are those that offer the ability to induce robust effector CD4+ and CD8+ T effector and memory responses. Cancer vaccines with such high-performance capacity are RNA, DNA, and SLP vaccines with the appropriate added or built-in adjuvants. The choice of target antigens for incorporation into cancer vaccines is of crucial importance, and viral- and mutation-based neoantigens, which are not subject to central thymus-driven tolerance, constitute very attractive targets. Additionally, selected CT and overexpressed antigens have demonstrated induction of potent tumoricidal T lymphocytes, but the T cell repertoires available against these antigens must be carefully scrutinized. In principle, differentiation antigens are less attractive targets, because the T cell repertoire against these is usually blunted and because powerful effector T cell generation against these antigens may cause serious toxicity. Because of the many T cell–suppressor activities in the cancer microenvironment (Figure 3A), cancer vaccines cannot be expected to show optimal anticancer efficacy by themselves, but need to be used in combination treatments that are designed to inactivate the most important immunosuppressive mechanisms in this environment. Many precision drugs that block immunosuppressive activities were recently identified (Figure 3B), contributing to many exciting new possibilities within the vaccine branch of cancer immunotherapy. Therapeutic vaccines offer the prospect of highly specific cancer therapies that are relatively inexpensive and noninvasive and can be effective in combination with standard chemo- or radiation therapies or with immunomodulatory drugs.

Acknowledgments

Writing of this review was supported by Dutch Cancer Society grant KWO 2009–4400, project leaders C.J.M. Melief and S.H. van der Burg.

Address correspondence to: Cornelis J.M. Melief, Leiden University Medical Center, PO Box 9600, Leiden, 2300 RC Leiden, Netherlands. Phone: 0031.71.5263800; E-mail: c.melief@lumc.nl.


36. de Martel C, et al. Global burden of cancers attributable to infections in 2008: a review and syn-
The Journal of Clinical Investigation

Review Series: Cancer Immunotherapy


22. Lemos H, Huang L, McGaha TL, Mellor AL. Cytosolic DNA sensing via the stimulator of...


